AI assistant
FDC Ltd. Earnings Release 2025
60812_rns_2025-02-12_c5ab665f-fd90-4d04-a6bb-c4492c02c0d5.pdf
Earnings Release
Open in viewerOpens in your device viewer
Date:- February 12, 2025
To, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400 001. BSE Script Code: 531599 NSE Symbol: FDC
National Stock Exchange of India Ltd. Exchange Plaza, Plot no. C/1, G Block, Bandra-Kurla Complex, Bandra (E), Mumbai - 400 051.
Sub: Press Release on Q3 - FY 2024-25 Results.
Dear Sir/Ma'am,
Please find attached herewith the Press Release issued in relation to the Unaudited Standalone and Consolidated Financial Results of the Company for the Quarter and nine months ended December 31, 2024.
Kindly take the same on record.
Thanking you,
Yours truly For FDC Limited VARSHAR ANI KATRE Digitally signed by VARSHARANI KATRE Date: 2025.02.12 18:05:07 +05'30'
Varsharani Katre Company Secretary & Compliance Officer M No.: FCS-8948
| CORPORATE OFFICE | : 142-48, S. V. Road, Jogeshwari (W), Mumbai - 400 102. INDIA Tel.: +91-22-6291 7900 / 950 / 2678 0652 / 2653 / 2656 ● Fax: +91-22-2677 3462 E-mail: [email protected] • Website: www.fdcindia.com |
|
|---|---|---|
| REGISTERED OFFICE | : B-8, M.I.D.C. Industrial Area, Waluj - 431 136, Dist. Aurangabad. INDIA Tel.: 0240-255 4407 / 255 4299 / 255 4967 • Fax: 0240-255 4299 E-mail: [email protected] • CIN: L24239MH1940PLC003176 |
MANUFACTURERS & EXPORTERS OF FOODS, DRUGS & CHEMICALS
FDC Limited reports Q3FY25 results
Mumbai, 12" Feb 2025: FDC Limited (NSE: FDC, BSE: 531599, ISIN: INE258B01022) reported financials for the second quarter ended 31* Dec 2024.
Consolidated Q3FY25 FDC and YMFY25 reported
| Rs. in crores | Q3FY25 | rwey | OMFY25 | oMFY2a | ||
|---|---|---|---|---|---|---|
| Operating Revenue | ||||||
| EBITDA | 47 | 84 | -44.3% | 269 | 282 | -4.7% |
| EBITDA % | 10.1% | 18.3% | 16.6% | 19:1% | ||
| PBT | 51 | 98 | -47.5% | 304 | 331 | -8.2% |
| PAT | 37 | 79 | -53.2% | 228 | 259 | -11.8% |
| EPS (Rs.) | 2.28 | 4.86 | -53.2% | 14.02 | 15.89 | -11.8% |
Commenting on the results;
The company delivered revenue growth of 9.1% in 9MFY25, driven by robust performance across all business segments, except for US Formulations. The export formulations business witnessed a 20.7% YoY decline in 9MFY25, primarily due to lower sales in the US market. On the other hand, the API business demonstrated strong momentum, recording a 25.6% YoY growth in Q3FY25 and 25.1% YoY growth in 9MFY25.
EBITDA for Q3FY25 and 9MFY25 was impacted by lower sales in export formulation business, price reduction in the Electral range of products, driven by NLEM price revisions changes in the product mix, and higher employee costs. )
CORPORATE OFFICE : 142-48, S. V. Road, Jogeshwari (W), Mumbai - 400 102. INDIA Tel.: +91-22-6291 7900 / 950 / 2678 0652 / 2653 / 2656 + Fax : +91-22-2677 3462 E-mail : [email protected] » Website : www.fdcindia.com
REGISTERED OFFICE : B-8, M.LD.C. Industrial Area, Waluj - 431 136, Dist. Aurangabad. INDIA Tel.: 0240-255 4407 / 255 4299 / 255 4967 + Fax : 0240-255 4299 E-mail : [email protected] + CIN : L24239MH1940PLC003176
MANUFACTURERS & EXPORTERS OF FOODS, DRUGS & CHEMICALS
| Q | 0 9 |
9 | 0 | |
|---|---|---|---|---|
| Net Sales | 464 | 1.3% | 1,616 | 9.1% |
| India Formulations | 388 | 6.9% | 1,358 | 13.7% |
| US Formulations | 8 | -75.7% | 54 | -52.1% |
| Emerging Markets 39 |
2.5% | 119 | 12.8% | |
| API Sales | 28 | 25.6% | 82 | 25.1% |
Business-wise Sales Performance
India Market:
The sale of branded formulations in India for Q3FY25 was Rs. 388 crores, with a growth of 6.9% on YoY and lower by 8.1% over QoQ. For the first nine months, sales were at Rs. 1,358 crores, a healthy growth of 13.7% over the same period last year. Overall sales in the Indian market accounted for 82% of total consolidated sales for the quarter and 84% for 9MFY25.
As per secondary sales data by IQVIA for the quarter ended Dec 31, 2024, the Company delivered YoY growth of 8.6% compared to the Indian Pharmaceutical Market (IPM) growth of 7.4% YoY. Electral has moved up to 20™ in IPM in MAT Dec'24 as compared to 23" in the same period last year.
Further, the company was the 5" fastest growing company as per MAT Dec'24 among the Top 25 companies.
Export Formulations Market:
Formulation Sales in the Export market were Rs. 47 crores in Q3FY25, down by 34.2% over YoY and lower by 23.2% over QoQ. For the first nine sales were Rs. 172 crores, down by 20.7% over the same period last year. Export formulation business impacted during the period primarily due to lower sales in USA markets.
During the quarter, the Company secured approval for one ANDA for Cefixime Tablets USP 400mg
API Business:
API business showed good traction of growth momentum with sales of Rs. 28 crores in Q3FY25, up by 25.6% over YoY and lower by 4.3% over QoQ and accounted for 6% of total consolidated sales. During 9MFY25, the API business grew by 25%, registering sales of Rs. 82crs.
MANUFACTURERS & EXPORTERS OF FOODS, DRUGS & CHEMICALS
ABOUT FDC LTD
FDC was established in the year 1936 as a partnership firm. This firm was incorporated as a Company in 1940, with the vision of building a world-class company while contributing to making the nation self-reliant in healthcare. To cite a few, FDC carries forward the flaming spirit of its first dream, achieving accreditations from the US-FDA, UK-MHRA, MCC-RSA, and the UAE. FDC is a forerunner in the manufacturing and marketing of Oral Rehydration Salts (ORS), anti-infectives and ophthalmic. FDC has also set up globally approved, multi-location manufacturing facilities for Active Pharmaceuticals Ingredients (APIs) as well as Finished Dosage Forms. These facilities are located at Roha, Waluj and Sinnar in Maharashtra, Verna in Goa and Baddi in Himachal Pradesh. FDC markets more than 300 products in India and exports many of these to over 50 countries. FDC strives to explore, innovate and integrate solutions with modern technology, empowering talent and expanding healthcare horizons for a better quality of life for millions globally.
Disclaimer
Except for the historical information contained herein, statements in this presentation and the subsecjuent discussions may constitute "forward-looking statements". These forward-looking statements involve several risks and uncertainties including the impact of Covid-19 and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, our ability to obtain regulatory approvals, technological changes, fluctuation in earnings, foreign exchange rates, our ability to manage international operations and exports, our exposure to market risks as well as other risks.
CORPORATE OFFICE : 142-48, S. V. Road, Jogeshwari (W), Mumbai - 400 102. INDIA Tel.: +91-22-6291 7900 / 950 / 2678 0652 / 2653 / 2656 * Fax : +91-22-2677 3462 E-mail : [email protected] * Website : www.fdcindia.com